US20060240004A1 - Methods for treating tweak-related conditions - Google Patents

Methods for treating tweak-related conditions Download PDF

Info

Publication number
US20060240004A1
US20060240004A1 US10/510,804 US51080405A US2006240004A1 US 20060240004 A1 US20060240004 A1 US 20060240004A1 US 51080405 A US51080405 A US 51080405A US 2006240004 A1 US2006240004 A1 US 2006240004A1
Authority
US
United States
Prior art keywords
tweak
cell
cells
antibody
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/510,804
Other languages
English (en)
Inventor
Linda Burkly
Aniela Jakubowski
Timothy Zheng
Kyungmin Hahm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen Idec MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec MA Inc filed Critical Biogen Idec MA Inc
Priority to US10/510,804 priority Critical patent/US20060240004A1/en
Assigned to BIOGEN IDEC MA INC. reassignment BIOGEN IDEC MA INC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: BIOGEN, INC.
Assigned to BIOGEN, INC. reassignment BIOGEN, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BURKLY, LINDA, HAHM, KYUNGMIN, JAKUBOWSKI, ANIELA, ZHENG, TIMOTHY
Publication of US20060240004A1 publication Critical patent/US20060240004A1/en
Priority to US12/417,755 priority patent/US8506958B2/en
Priority to US13/179,096 priority patent/US20120015024A1/en
Priority to US13/860,983 priority patent/US9011859B2/en
Priority to US14/661,391 priority patent/US20150291688A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
US10/510,804 2002-04-09 2003-04-09 Methods for treating tweak-related conditions Abandoned US20060240004A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US10/510,804 US20060240004A1 (en) 2002-04-09 2003-04-09 Methods for treating tweak-related conditions
US12/417,755 US8506958B2 (en) 2002-04-09 2009-04-03 Methods for treating TWEAK-related conditions
US13/179,096 US20120015024A1 (en) 2002-04-09 2011-07-08 Methods for treating tweak-related conditions
US13/860,983 US9011859B2 (en) 2002-04-09 2013-04-11 Methods for treating TWEAK-related conditions
US14/661,391 US20150291688A1 (en) 2002-04-09 2015-03-18 Methods For Treating Tweak-Related Conditions

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37161102P 2002-04-09 2002-04-09
US10/510,804 US20060240004A1 (en) 2002-04-09 2003-04-09 Methods for treating tweak-related conditions
PCT/US2003/011350 WO2003086311A2 (en) 2002-04-09 2003-04-09 Methods for treating tweak-related conditions

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/011350 A-371-Of-International WO2003086311A2 (en) 2002-04-09 2003-04-09 Methods for treating tweak-related conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/417,755 Continuation US8506958B2 (en) 2002-04-09 2009-04-03 Methods for treating TWEAK-related conditions

Publications (1)

Publication Number Publication Date
US20060240004A1 true US20060240004A1 (en) 2006-10-26

Family

ID=29250708

Family Applications (5)

Application Number Title Priority Date Filing Date
US10/510,804 Abandoned US20060240004A1 (en) 2002-04-09 2003-04-09 Methods for treating tweak-related conditions
US12/417,755 Expired - Fee Related US8506958B2 (en) 2002-04-09 2009-04-03 Methods for treating TWEAK-related conditions
US13/179,096 Abandoned US20120015024A1 (en) 2002-04-09 2011-07-08 Methods for treating tweak-related conditions
US13/860,983 Expired - Fee Related US9011859B2 (en) 2002-04-09 2013-04-11 Methods for treating TWEAK-related conditions
US14/661,391 Abandoned US20150291688A1 (en) 2002-04-09 2015-03-18 Methods For Treating Tweak-Related Conditions

Family Applications After (4)

Application Number Title Priority Date Filing Date
US12/417,755 Expired - Fee Related US8506958B2 (en) 2002-04-09 2009-04-03 Methods for treating TWEAK-related conditions
US13/179,096 Abandoned US20120015024A1 (en) 2002-04-09 2011-07-08 Methods for treating tweak-related conditions
US13/860,983 Expired - Fee Related US9011859B2 (en) 2002-04-09 2013-04-11 Methods for treating TWEAK-related conditions
US14/661,391 Abandoned US20150291688A1 (en) 2002-04-09 2015-03-18 Methods For Treating Tweak-Related Conditions

Country Status (20)

Country Link
US (5) US20060240004A1 (he)
EP (4) EP2301577A3 (he)
JP (4) JP2005536455A (he)
KR (2) KR101174214B1 (he)
CN (5) CN1658901A (he)
AU (1) AU2003224950B2 (he)
BR (1) BRPI0309126A8 (he)
CA (2) CA2887716C (he)
DK (1) DK1997512T3 (he)
EA (1) EA011607B1 (he)
ES (1) ES2444121T3 (he)
HK (1) HK1127545A1 (he)
IL (3) IL164352A0 (he)
MX (2) MXPA04009683A (he)
NO (2) NO334266B1 (he)
NZ (2) NZ548701A (he)
PT (1) PT1997512E (he)
SI (1) SI1997512T1 (he)
WO (1) WO2003086311A2 (he)
ZA (1) ZA200408073B (he)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006130429A2 (en) * 2005-05-27 2006-12-07 Biogen Idec Ma Inc. Treatment of cancer
US20070280940A1 (en) * 2004-12-13 2007-12-06 University Of Maryland, Baltimore Tweak as a Therapeutic Target for Treating Central Nervous System Diseases Associated with Cerebral Edema and Cell Death
US20080187544A1 (en) * 2005-05-10 2008-08-07 Burkly Linda C Treating and evaluating inflammatory disorders
US20080241163A1 (en) * 2005-05-27 2008-10-02 Biogen Idec Ma Inc. Tweak binding antibodies
US20080292622A1 (en) * 2005-06-13 2008-11-27 Biogen Idec Ma Inc. Methods of evaluating patients
US20090068102A1 (en) * 2005-02-17 2009-03-12 Biogen Idec Ma Inc. Treating stroke
US20090124993A1 (en) * 2005-02-17 2009-05-14 Burkly Linda C Treating neurological disorders
WO2010019234A1 (en) * 2008-08-12 2010-02-18 Ihc Intellectual Asset Management, Llc Analysis of genetic markers for peripartum cardiomyopathy
US20100061985A1 (en) * 1999-01-15 2010-03-11 Biogen Idec Ma Inc. Antagonists of tweak and of tweak receptor and their use to treat immunological disorders
WO2010088534A1 (en) * 2009-01-30 2010-08-05 Biogen Idec Ma Inc. Methods for pancreatic tissue regeneration
US20100260761A1 (en) * 1996-08-07 2010-10-14 Biogen, Inc. Antibodies specifically reactive with a tumor necrosis factor related ligand
WO2011097500A2 (en) * 2010-02-04 2011-08-11 University Of Louisville Research Foundation, Inc. The tweak/fn14 system regulates skeletal muscle atrophy and regeneration
US8093006B2 (en) 2009-04-02 2012-01-10 Hoffmann-La Roche Inc. Antibodies against human tweak and uses thereof
US9011859B2 (en) 2002-04-09 2015-04-21 Biogen Idec Ma Inc. Methods for treating TWEAK-related conditions
US9096879B2 (en) * 2009-11-24 2015-08-04 Biogen Ma Inc. Method of supplementing culture media to prevent undesirable amino acid substitutions

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004500844A (ja) 2000-05-08 2004-01-15 バイオジェン　インコーポレイテッド Ｔｗｅａｋアゴニストおよび血管形成因子を使用する、新血管新生を促進するための方法
US7208151B2 (en) 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
WO2005053728A2 (de) * 2003-12-01 2005-06-16 Xantos Biomedicine Ag Mit adipositas assoziierte proteine und deren verwendung in therapie und diagnostik
AU2011239311B2 (en) * 2005-02-17 2014-05-22 Biogen Ma Inc. Treating Neurological Disorders
EP1764109A1 (de) * 2005-05-24 2007-03-21 Xantos Biomedicine AG Agonistische Antikörper, welche an den Tweak Rezeptor Fn14 binden und dadurch Adipositas assoziierte Phänotypen modulieren, und deren Verwendung in der Therapie
WO2006125632A2 (en) * 2005-05-24 2006-11-30 Rechtsanwalt Dr. Martin Prager Als Insolvenzverwalter Über Das Vermögen Der Xantos Biomedicine Ag, Pluta Rechtsanwalts Gmbh Agonistic antibodies that bind to the tweak receptor fn14 and thereby modulate adiposity-associated phenotypes as well as their use in therapy
US8039437B2 (en) 2008-06-30 2011-10-18 The Trustees Of The University Of Pennsylvania Fn14/TRAIL fusion proteins
JP5161718B2 (ja) * 2008-09-25 2013-03-13 株式会社ゲノム創薬研究所 肝障害モデル動物、及びそれを用いた肝障害を改善又は予防する、薬剤若しくは食品素材のスクリーニング方法
CN103153332A (zh) 2010-09-28 2013-06-12 卡尔医疗有限公司 用于治疗血液恶性肿瘤的组合物和方法
EP2625200A1 (en) 2010-10-05 2013-08-14 F.Hoffmann-La Roche Ag Antibodies against human tweak and uses thereof
RU2462222C1 (ru) * 2011-07-11 2012-09-27 Наталья Николаевна Молчанова Способ лечения больных артериальной гипертонией с метаболическими нарушениями
ES2748021T3 (es) 2011-08-23 2020-03-12 Univ La Trobe Proteínas de unión a Fn14 y usos de las mismas
WO2013150043A1 (en) 2012-04-05 2013-10-10 F. Hoffmann-La Roche Ag Bispecific antibodies against human tweak and human il17 and uses thereof
GB201317929D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
US10744178B2 (en) * 2014-08-21 2020-08-18 Stealth Biotherapeutics Corp Methods and compositions for the prevention and treatment of disease
WO2016061632A1 (en) * 2014-10-23 2016-04-28 La Trobe University Fn14-binding proteins and uses thereof
KR101881531B1 (ko) * 2016-11-25 2018-07-25 고려대학교 산학협력단 폴리-2-하이드록시에틸 메타아크릴레이트를 이용한 사이토카인의 발현능이 증가된 줄기세포의 제조방법
CN113616777A (zh) * 2021-08-18 2021-11-09 中山大学附属第三医院（中山大学肝脏病医院） 基于主要尿蛋白改善内质网应激的转化应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020015703A1 (en) * 1999-01-15 2002-02-07 Paul Rennert Antagonists of tweak and of tweak receptor and their use to treat immunological disorders

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US5200313A (en) 1983-08-05 1993-04-06 Miles Inc. Nucleic acid hybridization assay employing detectable anti-hybrid antibodies
US4921698A (en) 1984-05-25 1990-05-01 Asahi Kasei Kogyo Kabushiki Kaisha Polypeptide having gamma-interferon activity lacking amino acids coded by exon 4
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE122007000007I1 (de) 1986-04-09 2007-05-16 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US5073492A (en) 1987-01-09 1991-12-17 The Johns Hopkins University Synergistic composition for endothelial cell growth
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
AT396939B (de) 1990-05-29 1993-12-27 Alois Dipl Ing Dr Jungbauer Komplexes virales antigen von hiv-1 bindendes rekombinantes protein
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
PT1696031E (pt) 1991-12-02 2010-06-25 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
CA2153480A1 (en) 1993-11-12 1995-06-01 Kenichi Matsubara Gene signature
US20030198640A1 (en) 1994-11-07 2003-10-23 Human Genome Sciences, Inc. Methods and compositions for treating inflammatory bowel diseases relating to human tumor necrosis factor-gamma-beta
ES2281898T3 (es) 1994-12-13 2007-10-01 Human Genome Sciences, Inc. Inhibidor tisular humano de metaloproteinasa-4.
US6544761B2 (en) 1994-12-13 2003-04-08 Human Genome Sciences, Inc. Human tissue inhibitor of metalloproteinase-4
PT859841E (pt) 1995-08-18 2002-11-29 Morphosys Ag Bibliotecas de proteinas/ (poli) peptidos
US5994619A (en) 1996-04-01 1999-11-30 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus Production of chimeric bovine or porcine animals using cultured inner cell mass cells
US7129061B1 (en) 1996-08-07 2006-10-31 Biogen Idec Ma Inc. Tumor necrosis factor related ligand
NZ334107A (en) 1996-08-07 2000-06-23 Faculty Of Medicine Of The Uni A tumor necrosis factor (TNF) related ligand (TRELL), modified TRELL and pharmaceutical compositions comprising them
US5858991A (en) 1997-01-29 1999-01-12 Vanderbilt University Facilitation of wound healing with CM101/GBS toxin
JP2001513626A (ja) * 1997-02-12 2001-09-04 アボツト・ラボラトリーズ 疾患の治療及び診断のために有用なｔｎｆファミリーのメンバー
JP2002512624A (ja) 1997-05-21 2002-04-23 バイオベーション リミテッド 非免疫原性タンパク質の製造方法
CA2293296A1 (en) 1997-06-03 1998-12-10 Sagami Chemical Research Center Human proteins having transmembrane domains and dnas encoding these proteins
AU9376498A (en) 1997-09-05 1999-03-22 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
CA2303225C (en) 1997-09-18 2015-03-31 Genentech, Inc. Dna30942 polypeptide, a tnfr homolog
AU749948B2 (en) 1997-10-10 2002-07-04 Genentech Inc. APO-3 ligand
US20020072089A1 (en) 1999-11-23 2002-06-13 Holtzman Douglas A. Novel ITALY, Lor-2, STRIFE, TRASH, BDSF, LRSG, and STMST protein and nucleic acid molecules and uses therefor
US6046381A (en) * 1998-04-30 2000-04-04 The Regents Of The University Of California Apolipoprotein E transgenic mice and assay methods
AU4672199A (en) 1998-05-20 1999-12-06 Yale University Modulation of angiogenesis and wound healing
EP1080194A2 (en) 1998-05-29 2001-03-07 Incyte Pharmaceuticals, Inc. Human transmembrane proteins
CA2345382A1 (en) 1998-10-16 2000-04-27 Immunex Corporation Inhibitors of platelet activation and recruitment
ES2278463T3 (es) 1998-12-08 2007-08-01 Biovation Limited Metodo para reducir la inmunogenicidad de proteinas.
KR100499600B1 (ko) 1998-12-22 2005-07-07 제넨테크, 인크. 신생 세포 성장을 억제하기 위한 방법 및 조성물
US20020004041A1 (en) 1999-02-19 2002-01-10 Albert Matthew L. Methods for abrogating a cellular immune response
PT1632499E (pt) 1999-03-08 2007-09-11 Genentech Inc Dispositivo de detecção de impacto para automóveis.
US6521424B2 (en) 1999-06-07 2003-02-18 Immunex Corporation Recombinant expression of Tek antagonists
KR20050004240A (ko) 1999-08-31 2005-01-12 제넨테크, 인크. 종양 치료용 조성물 및 방법
WO2001045730A2 (en) * 1999-12-20 2001-06-28 Immunex Corporation Tweak receptor
US6727225B2 (en) 1999-12-20 2004-04-27 Immunex Corporation TWEAK receptor
US7495086B2 (en) 1999-12-20 2009-02-24 Immunex Corporation TWEAK receptor
DE60127933T2 (de) 2000-01-03 2008-02-07 Mark L. Merion Station Tykocinski Chimäre proteine und anwendungen
US7927602B2 (en) 2002-07-23 2011-04-19 University Of Louisville Research Foundation, Inc. Fas ligand-avidin/streptavidin fusion proteins
WO2001062905A2 (en) 2000-02-25 2001-08-30 Immunex Corporation Integrin antagonists
JP2004500844A (ja) 2000-05-08 2004-01-15 バイオジェン　インコーポレイテッド Ｔｗｅａｋアゴニストおよび血管形成因子を使用する、新血管新生を促進するための方法
US7498304B2 (en) 2000-06-16 2009-03-03 Curis, Inc. Angiogenesis-modulating compositions and uses
US20040047854A1 (en) 2001-07-27 2004-03-11 Black Roy A. Human disintegrin protein
US7208151B2 (en) 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
AU8901901A (en) * 2000-09-14 2002-03-26 Biogen Inc Tweak receptor agonists as anti-angiogenic agents background
EP1354950A4 (en) 2000-12-28 2005-01-12 Asahi Kasei Pharma Corp ACTIVATION GENE OF NF-KB
CA2441702A1 (en) 2001-03-21 2002-12-27 Human Genome Sciences, Inc. Human secreted proteins
US20040203083A1 (en) 2001-04-13 2004-10-14 Biosite, Inc. Use of thrombus precursor protein and monocyte chemoattractant protein as diagnostic and prognostic indicators in vascular diseases
US20040076955A1 (en) 2001-07-03 2004-04-22 Eos Biotechnology, Inc. Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
AU2002363354A1 (en) 2001-07-27 2003-05-19 Human Genome Sciences, Inc. Heteromultimeric tnf ligand family members
US20040091473A1 (en) 2001-07-27 2004-05-13 Dubose Robert F. Metalloproteinase-disintegrin polypeptides and methods of making and use thereof
US20030148314A1 (en) 2001-08-01 2003-08-07 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of colon cancer
US20040033495A1 (en) 2001-08-03 2004-02-19 Eos Biotechnology, Inc. Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
AU2002366433A1 (en) 2001-08-16 2003-09-09 Human Genome Sciences, Inc. Methods and compositions for treating metabolic bone diseases relating to human endokine alpha
EP2301577A3 (en) 2002-04-09 2012-08-08 Biogen Idec MA Inc. Methods for treating TWEAK-related conditions
US20050181375A1 (en) 2003-01-10 2005-08-18 Natasha Aziz Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer
WO2004065416A2 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
WO2004074506A2 (en) 2003-02-13 2004-09-02 Mergen Ltd Polynucleotide sequences and corresponding encoded polypeptides of particular secreted and membrane-bound proteins overexpressed in certain cancers
US20050008625A1 (en) 2003-02-13 2005-01-13 Kalobios, Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
EP1599607A2 (en) 2003-03-04 2005-11-30 Arcturus Bioscience, Inc. Signatures of er status in breast cancer
ES2287773T3 (es) 2003-07-24 2007-12-16 Amgen Inc. Composiciones y metodos relacionados con fragmentos solubles multimericos y oligomericos del receptor tweak.
EP1566636A1 (en) 2004-02-23 2005-08-24 AXARON Bioscience AG Use of Tweak modulators and inhibitors for the treatment of neurological conditions
EP1811838A4 (en) 2004-11-08 2009-07-22 Univ Maryland TWEAK AS A THERAPEUTIC TARGET FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM IN CONNECTION WITH CEREBRAL OEDEM AND CELL DEATH
US7939490B2 (en) 2004-12-13 2011-05-10 University Of Maryland, Baltimore TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
DK2529619T3 (en) 2005-02-17 2016-01-11 Biogen Ma Inc Treatment of neurological disorders
WO2006088890A2 (en) 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating stroke
JP2008531746A (ja) 2005-03-07 2008-08-14 ジェネンテック・インコーポレーテッド Ｔｗｅａｋ及びｆｎ１４活性を調節するための方法及び組成物
JP5339901B2 (ja) 2005-05-10 2013-11-13 バイオジェン・アイデック・エムエイ・インコーポレイテッド 炎症傷害の処置および評価
SI1888113T1 (sl) 2005-05-27 2014-10-30 Biogen Idec Ma Inc. Protitelesa, ki veĹľejo TWEAK
WO2006130429A2 (en) 2005-05-27 2006-12-07 Biogen Idec Ma Inc. Treatment of cancer
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
US20100284933A1 (en) 2006-10-16 2010-11-11 Biogen Idec Ma Inc. Biomarkers of Multiple Sclerosis
AU2009246640A1 (en) 2008-05-15 2009-11-19 Biogen Idec Ma Inc. Anti-Fn14 antibodies and uses thereof
WO2010085648A2 (en) 2009-01-23 2010-07-29 Linda Burkly C Methods for reducing radiation-induced tissue damage
AU2010208123A1 (en) 2009-01-30 2011-08-18 Biogen Idec Ma Inc. Methods for pancreatic tissue regeneration
EP2625200A1 (en) 2010-10-05 2013-08-14 F.Hoffmann-La Roche Ag Antibodies against human tweak and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020015703A1 (en) * 1999-01-15 2002-02-07 Paul Rennert Antagonists of tweak and of tweak receptor and their use to treat immunological disorders

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100260761A1 (en) * 1996-08-07 2010-10-14 Biogen, Inc. Antibodies specifically reactive with a tumor necrosis factor related ligand
US20100061985A1 (en) * 1999-01-15 2010-03-11 Biogen Idec Ma Inc. Antagonists of tweak and of tweak receptor and their use to treat immunological disorders
US8440189B2 (en) 1999-01-15 2013-05-14 Biogen Idec Ma Inc. Antagonists of TWEAK and of TWEAK receptor and their use to treat immunological disorders
US9011859B2 (en) 2002-04-09 2015-04-21 Biogen Idec Ma Inc. Methods for treating TWEAK-related conditions
US20070280940A1 (en) * 2004-12-13 2007-12-06 University Of Maryland, Baltimore Tweak as a Therapeutic Target for Treating Central Nervous System Diseases Associated with Cerebral Edema and Cell Death
US7939490B2 (en) * 2004-12-13 2011-05-10 University Of Maryland, Baltimore TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
US9775899B2 (en) 2005-02-17 2017-10-03 Biogen Ma Inc. Treating neurological disorders
US20090068102A1 (en) * 2005-02-17 2009-03-12 Biogen Idec Ma Inc. Treating stroke
US20090124993A1 (en) * 2005-02-17 2009-05-14 Burkly Linda C Treating neurological disorders
US8728475B2 (en) 2005-05-10 2014-05-20 Biogen Idec Ma Inc. Methods for treating inflammatory bowel disease
US20080187544A1 (en) * 2005-05-10 2008-08-07 Burkly Linda C Treating and evaluating inflammatory disorders
US20080279853A1 (en) * 2005-05-27 2008-11-13 Biogen Idec Ma Inc. Treatment of cancer
WO2006130429A3 (en) * 2005-05-27 2008-11-20 Biogen Idec Inc Treatment of cancer
US20080241163A1 (en) * 2005-05-27 2008-10-02 Biogen Idec Ma Inc. Tweak binding antibodies
WO2006130429A2 (en) * 2005-05-27 2006-12-07 Biogen Idec Ma Inc. Treatment of cancer
US8048422B2 (en) 2005-05-27 2011-11-01 Biogen Idec Ma Inc. Tweak binding antibodies
US8048635B2 (en) 2005-06-13 2011-11-01 Biogen Idec Ma Inc. Measurement of soluble Tweak levels for evaluation of lupus patients
US20080292622A1 (en) * 2005-06-13 2008-11-27 Biogen Idec Ma Inc. Methods of evaluating patients
US9730947B2 (en) 2005-06-13 2017-08-15 Biogen Ma Inc. Method of treating lupus nephritis
WO2010019234A1 (en) * 2008-08-12 2010-02-18 Ihc Intellectual Asset Management, Llc Analysis of genetic markers for peripartum cardiomyopathy
US20120020913A1 (en) * 2009-01-30 2012-01-26 Biogen Idec Ma Inc. Methods for pancreatic tissue regeneration
WO2010088534A1 (en) * 2009-01-30 2010-08-05 Biogen Idec Ma Inc. Methods for pancreatic tissue regeneration
US8883976B2 (en) 2009-04-02 2014-11-11 Hoffmann-La Roche Inc. Antibodies against human tweak and uses thereof
US8852887B2 (en) 2009-04-02 2014-10-07 Hoffmann-La Roche Inc. Antibodies against human tweak and uses thereof
US8093006B2 (en) 2009-04-02 2012-01-10 Hoffmann-La Roche Inc. Antibodies against human tweak and uses thereof
US9096879B2 (en) * 2009-11-24 2015-08-04 Biogen Ma Inc. Method of supplementing culture media to prevent undesirable amino acid substitutions
WO2011097500A3 (en) * 2010-02-04 2011-12-29 University Of Louisville Research Foundation, Inc. The tweak/fn14 system regulates skeletal muscle atrophy and regeneration
WO2011097500A2 (en) * 2010-02-04 2011-08-11 University Of Louisville Research Foundation, Inc. The tweak/fn14 system regulates skeletal muscle atrophy and regeneration
US9068004B2 (en) 2010-02-04 2015-06-30 University Of Louisville Research Foundation, Inc. TWEAK/Fn14 system regulates skeletal muscle atrophy and regeneration
US9751950B2 (en) 2010-02-04 2017-09-05 University Of Louisville Research Foundation, Inc. Methods of reducing skeletal muscle loss using an antibody against Fn14

Also Published As

Publication number Publication date
EP2301577A2 (en) 2011-03-30
EA200401329A1 (ru) 2005-10-27
EP2301577A3 (en) 2012-08-08
EP1494713A4 (en) 2005-12-28
WO2003086311A2 (en) 2003-10-23
JP2005536455A (ja) 2005-12-02
CN106421778A (zh) 2017-02-22
AU2003224950A1 (en) 2003-10-27
KR20100099348A (ko) 2010-09-10
JP5916776B2 (ja) 2016-05-11
US20150291688A1 (en) 2015-10-15
CN101683520A (zh) 2010-03-31
HK1127545A1 (en) 2009-10-02
CA2887716A1 (en) 2003-10-23
KR101000842B1 (ko) 2010-12-14
IL164352A (he) 2016-08-31
IL230158B (he) 2018-06-28
EP1997512A3 (en) 2009-03-11
BR0309126A (pt) 2005-06-07
US20120015024A1 (en) 2012-01-19
US20090311313A1 (en) 2009-12-17
EP1494713A2 (en) 2005-01-12
EP2301578A3 (en) 2012-08-08
JP2014132004A (ja) 2014-07-17
MXPA04009683A (es) 2005-01-11
KR20040111500A (ko) 2004-12-31
WO2003086311A3 (en) 2004-06-24
AU2003224950B2 (en) 2006-09-14
BRPI0309126A8 (pt) 2017-03-07
PT1997512E (pt) 2014-02-20
EP2301578A2 (en) 2011-03-30
ZA200408073B (en) 2006-06-28
JP5603040B2 (ja) 2014-10-08
NO20131617L (no) 2005-01-07
EP1997512B1 (en) 2013-12-04
NO338778B1 (no) 2016-10-17
NZ536348A (en) 2007-05-31
CN102793921A (zh) 2012-11-28
US8506958B2 (en) 2013-08-13
CN103536916A (zh) 2014-01-29
JP2012021014A (ja) 2012-02-02
DK1997512T3 (da) 2014-01-27
CA2887716C (en) 2017-01-24
EP1997512A2 (en) 2008-12-03
US20130216496A1 (en) 2013-08-22
NZ548701A (en) 2008-03-28
NO20044857L (no) 2005-01-07
JP2009286793A (ja) 2009-12-10
MX352180B (es) 2017-11-13
IL164352A0 (en) 2005-12-18
NO334266B1 (no) 2014-01-27
ES2444121T3 (es) 2014-02-24
SI1997512T1 (sl) 2014-03-31
KR101174214B1 (ko) 2012-08-14
US9011859B2 (en) 2015-04-21
CN103536916B (zh) 2016-08-17
CN1658901A (zh) 2005-08-24
CA2480745A1 (en) 2003-10-23
EA011607B1 (ru) 2009-04-28

Similar Documents

Publication Publication Date Title
US9011859B2 (en) Methods for treating TWEAK-related conditions
JP2001526532A (ja) オステオプロテゲリン結合性蛋白および受容体
JP2009256359A (ja) 血管形成抑制剤
KR20100016045A (ko) 염증성 질환의 치료를 위한 ｃｘｃｌ１３ 길항제 및 이의 용도
AU2006252060B2 (en) Methods for Treating TWEAK-related Conditions
WO2006019193A1 (ja) 阻害剤・促進剤の用途
US20060147448A1 (en) Treatment of immunological renal disorders by lymphotoxin pathway inhibitors

Legal Events

Date Code Title Description
AS Assignment

Owner name: BIOGEN IDEC MA INC.,MASSACHUSETTS

Free format text: CHANGE OF NAME;ASSIGNOR:BIOGEN, INC.;REEL/FRAME:018291/0765

Effective date: 20031113

Owner name: BIOGEN IDEC MA INC., MASSACHUSETTS

Free format text: CHANGE OF NAME;ASSIGNOR:BIOGEN, INC.;REEL/FRAME:018291/0765

Effective date: 20031113

Owner name: BIOGEN, INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BURKLY, LINDA;JAKUBOWSKI, ANIELA;ZHENG, TIMOTHY;AND OTHERS;REEL/FRAME:018293/0829

Effective date: 20030324

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION